AAAAAA

   
Results: 1-14 |
Results: 14
Lactacystin inhibits cathepsin A activity in melanoma cell lines
Authors: Kozlowski, L Stoklosa, T Omura, S Wojcik, C Wojtukiewicz, MZ Worowski, K Ostrowska, H
Citation: L. Kozlowski et al., Lactacystin inhibits cathepsin A activity in melanoma cell lines, TUMOR BIOL, 22(4), 2001, pp. 211-215
Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo
Authors: Golab, J Zagozdzon, R Kaminski, R Kozar, K Gryska, K Izycki, D Mackiewicz, A Stoklosa, T Giermasz, A Lasek, W Jakobisiak, M
Citation: J. Golab et al., Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo, LEUKEMIA, 15(4), 2001, pp. 613-620
Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in humanpromonocytic leukemic U937 cells
Authors: Mlynarczuk, I Hoser, G Grzela, T Stoklosa, T Wojcik, C Malejczyk, J Jakobisiak, M
Citation: I. Mlynarczuk et al., Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in humanpromonocytic leukemic U937 cells, ANTICANC R, 21(2A), 2001, pp. 1237-1240
Lovastatin and simvastatin are modulators of the proteasome
Authors: Wojcik, C Bury, M Stoklosa, T Giermasz, A Feleszko, W Mlynarczuk, I Pleban, E Basak, G Omura, S Jakobisiak, M
Citation: C. Wojcik et al., Lovastatin and simvastatin are modulators of the proteasome, INT J BIO C, 32(9), 2000, pp. 957-965
Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome
Authors: Ostrowska, H Wojcik, C Wilk, S Omura, S Kozlowski, L Stoklosa, T Worowski, K Radziwon, P
Citation: H. Ostrowska et al., Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome, INT J BIO C, 32(7), 2000, pp. 747-757
Lovastatin potentiates antitumor activity and attenuates cardiotoxicity ofdoxorubicin in three tumor models in mice
Authors: Feleszko, W Mlynarczuk, I Balkowiec-Iskra, EZ Czajka, A Switaj, T Stoklosa, T Giermasz, A Jakobisiak, M
Citation: W. Feleszko et al., Lovastatin potentiates antitumor activity and attenuates cardiotoxicity ofdoxorubicin in three tumor models in mice, CLIN CANC R, 6(5), 2000, pp. 2044-2052
Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo
Authors: Golab, J Zagozdzon, R Kozar, K Kaminski, R Giermasz, A Stoklosa, T Lasek, W Jakobisiak, M
Citation: J. Golab et al., Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo, ONCOL REP, 7(1), 2000, pp. 177-181
Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice
Authors: Golab, J Stoklosa, T Czajka, A Dabrowska, A Jakobisiak, M Zagozdzon, R Wojcik, C Marczak, M Wilk, S
Citation: J. Golab et al., Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice, ANTICANC R, 20(3A), 2000, pp. 1717-1721
Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice
Authors: Golab, J Kozar, K Kaminski, R Czajka, A Marczak, M Switaj, T Giermasz, A Stoklosa, T Lasek, W Zagozdzon, R Mucha, K Jakobisiak, M
Citation: J. Golab et al., Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice, LIFE SCI, 66(13), 2000, pp. 1223-1230
Potentiation of the anti-tumour effects of Photofrin (R)-based photodynamic therapy by localized treatment with G-CSF
Authors: Golab, J Wilczynski, G Zagozdzon, R Stoklosa, T Dabrowska, A Rybczynska, J Wasik, M Machaj, E Oldak, T Kozar, K Kaminski, R Giermasz, A Czajka, A Lasek, W Feleszko, W Jakobisiak, M
Citation: J. Golab et al., Potentiation of the anti-tumour effects of Photofrin (R)-based photodynamic therapy by localized treatment with G-CSF, BR J CANC, 82(8), 2000, pp. 1485-1491
Subtherapeutic doses of interleukin-15 augment the anti-tumor effect of interleukin-12 in a B16F10 melanoma model in mice
Authors: Lasek, W Golab, J Maslinski, W Switaj, T Balkowiec, EZ Stoklosa, T Giermasz, A Malejczyk, M Jakobisiak, M
Citation: W. Lasek et al., Subtherapeutic doses of interleukin-15 augment the anti-tumor effect of interleukin-12 in a B16F10 melanoma model in mice, EUR CYTOKIN, 10(3), 1999, pp. 345-356
The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production
Authors: Zagozdzon, R Giermasz, A Golab, J Stoklosa, T Jalili, A Jakobisiak, M
Citation: R. Zagozdzon et al., The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production, CANCER LETT, 147(1-2), 1999, pp. 67-75
Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together?
Authors: Stoklosa, T Wojcik, C Golab, J Giermasz, A Wilk, S
Citation: T. Stoklosa et al., Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together?, BR J CANC, 79(2), 1999, pp. 375-376
A combination of retinoic acid and proteasome inhibitors for the treatmentof leukemias is potentially dangerous
Authors: Wojcik, C Mlynarczuk, I Hoser, G Kawiak, J Stoklosa, T Golab, J Wilk, S
Citation: C. Wojcik et al., A combination of retinoic acid and proteasome inhibitors for the treatmentof leukemias is potentially dangerous, BLOOD, 94(5), 1999, pp. 1827-1828
Risultati: 1-14 |